|
Technologies
Avecia is committed to an ongoing strategic
R&D programme whose goal is the creation of new process technologies
that can bring major advantages to our customers in time, cost
and quality. This is backed-up by focused technology licensing.
Our use of the phrase 'Transforming Technologies' headlines what
we seek to achieve. Our focus is across the entire process from
gene to downstream to GMP operations. We have been at the forefront
of applying disposable technologies in manufacture and our launch
of pAVEway in 2007 has already delivered process advantages by
addressing strain, construct and fermentation. Our goal is to
maintain a flow of valuable and proven technologies that make
our process creation and development work second to none and deliver
benefits including:
- improved process productivity
- improved product quality
- lower cost of goods
pAVEway™
Avecia has added pAVEway™ to its growing
portfolio of advanced technology solutions for the manufacture
of therapeutic proteins. This new technology enables class-leading
(>10g/L) microbial production of a wide range of therapeutically
useful proteins (vaccines, cytokines, growth factors, etc).
Avecia’s scientists have used their expertise
and understanding of the expression kinetics of existing state-of-the-art
microbial systems to design and build a range of innovative expression
vectors, to select a range of suitable host cells and to optimise
the fermentation processes. These systems are combined in the
pAVEway platform, which offers a way for fast track process creation
and development. Among the unique features of pAVEway are the
fully repressible basic expression and the modulatable expression
induction. This enables the high level expression of a wider range
of proteins than ever before.
pAVEway will help to reduce the time to market
and cost, while increasing flexibility and maintaining Avecia’s
high quality standards.
Click here
for .pdf file of pAVEway™ brochure
Listen to Bo Kara,
Director of Science & Technology, talk about the benefits
of pAVEway™.
The Yeast Experts Yeasts
are able to secrete correctly folded protein into culture supernatants
and achieve this even with complicated proteins. They are also
able to achieve valuable post-translational modifications such
as glycosylation. These and other characteristics have made them
a focus for many companies seeking cost-effective and highly productive
operations. The many high-profile deals involving yeast-based
products, spanning biotech and pharma, are testimony to this trend.
For over ten years Avecia has been developing, scaling-up and
operating processes for yeast-derived biologics at scales of 100
litre, 1000 litre and 5000 litre. Processes taken through validation
have demonstrated high consistency of performance and robustness
making them suitable for intensive commercial operations.
Avecia has brought together the package of experience and technologies
that combined provide a powerful and unparalleled competence for
yeast-derived biologics. |
|
